Drugs - NanoMedicines Research Group

Login Form

Drugs

The following nanomedicines have been co-developed by the UBC NanoMedicines Research Group and industry partners:

 Drug  Trade Name  Indication  Status (2019)  Company
 LNP Amphotericin  ABELCET  Fungal infections  Approved US, 1995  Enzon
 LNP Doxorubicin  Myocet  Metastatic breast cancer  Approved Europe 2000  Cephalon
 LNP Vincristine  Marqibo  Acute lymphoblastic leukemia  Approved US, 2012  Acrotec Biopharma
 LNP siRNA TTR  Onpattro (Patisiran)  Transthyretin-induced amyloidosis  Approved US, Europe, 2018  Alnylam
Copyright